Ascendis Pharma A/S
ASND
View Detailed Chart
205.710USD
-0.200-0.10%
Close 10/29, 16:00（ET）Quotes delayed by 15 min
12.58BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.10%
5 Days
+2.55%
1 Month
+7.15%
6 Months
+24.76%
Year to Date
+49.42%
1 Year
+58.92%
View Detailed Chart
TradingKey Stock Score of Ascendis Pharma A/S
Currency: USD Updated: 2025-10-28Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ascendis Pharma A/S's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
17
analysts
Buy
Current Rating
255.918
Target Price
+25.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ascendis Pharma A/S Highlights
StrengthsRisks
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 719.04% year-on-year.
Undervalued
The company’s latest PE is -20.29, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 64.58M shares, decreasing 9.25% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 23.00K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Ascendis Pharma A/S Info
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ticker SymbolASND
CompanyAscendis Pharma A/S
CEOMr. Jan Moller Mikkelsen
Websitehttps://ascendispharma.dk/
Related Instruments
-1.72%
-0.11%
-12.52%
+1.00%
-0.63%
-1.60%
+0.70%
+2.60%
-2.96%
-6.63%
-0.88%
-2.30%
-0.26%
-1.61%
-1.56%
-3.00%
-1.77%
-4.89%
-4.19%
-3.88%Popular Symbols
